It is no secret that pharmaceutical and biotech companies are beginning to invest heavily in the rare disease space. One of the attractions is that orphan drugs, developed for the treatment of rare and ultra-rare disorders, tend to be very expensive, where single patient costs can reach $350,000 and above per year.